Comparison of DPP-4 Inhibitors.
10.4093/jkd.2013.14.3.111
- Author:
Nam Hoon KIM
1
;
Sin Gon KIM
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. k50367@korea.ac.kr
- Publication Type:Editorial
- Keywords:
Dipeptidyl-peptidase IV inhibitors;
Incretins;
Diabetes mellitus
- MeSH:
Adamantane;
Diabetes Mellitus;
Dipeptides;
Dipeptidyl-Peptidase IV Inhibitors;
Hypoglycemia;
Hypoglycemic Agents;
Incretins;
Insulin;
Nitriles;
Piperidines;
Purines;
Pyrazines;
Pyrrolidines;
Quinazolines;
Triazoles;
Uracil;
Linagliptin;
Sitagliptin Phosphate
- From:Journal of Korean Diabetes
2013;14(3):111-119
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
During past several years, a novel class of antihyperglycemic agents, dipeptidyl peptidase-4 (DPP-4) inhibitors, has become one of the most important options in the management of type 2 diabetes. These agents have unique insulinotropic actions as well as other advantages such as lower hypoglycemia and a weight-neutral effect compared to traditional insulin secretagogues. To date, 6 different DPP-4 inhibitors have been introduced: sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin and gemiglitin. This review provides a summary of the clinical data for each DPP-4 inhibitor, and discusses the similarities and differences between them.
